Anthrax
📧 Sign up to get email alerts when something new happens for Anthrax.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
This is an observational study evaluating raxibacumab for sporadic systemic anthrax cases, sponsored by Emergent BioSolutions, and not yet r…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Clinical trial update for the SPoRE natural history study of anthrax and an evaluation of AVA-vaccinated recipients. Sponsored by NIAID, wit…
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Anthrax AV7909 Boost Evaluation Study [Phase 2]
This ClinicalTrials.gov entry reports a Phase 2 study evaluating the Anthrax vaccine AV7909 booster, and it is currently active but not recr…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
Observational study evaluating the clinical benefit and safety of AIGIV (ANTHRASIL) in patients with systemic anthrax; sponsor Emergent BioS…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
This clinical trial is evaluating the clinical benefit and safety of CYFENDUS for post-exposure prophylaxis of anthrax and is currently not …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: Anthrax AV7909 Liquid vs Lyophilized [Phase 1]
Phase 1 trial comparing liquid versus lyophilized AV7909 anthrax vaccine formulations completed, with results posted.
-
EMA withdrawal · 2024-09-09EMA Withdrawn: Nyxthracis (previously Obiltoxaximab SFL) (nyxthracis) — SFL Pharmaceuticals Deutschland GmbH
EMA has withdrawn Nyxthracis (formerly Obiltoxaximab SFL) from the market for anthrax.
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change [Phase 4]
Phase 4 trial evaluating dose reduction and route changes for an anthrax vaccine in healthy participants; results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-07-14Clinical Trial Update: An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis [Phase 4]
Open-label Phase 4 study evaluating Anthim (obiltoxaximab) in individuals exposed to Bacillus anthracis (anthrax).
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 [Phase 2]
Phase 2 trial evaluating dose-response, efficacy (immunogenicity) and safety of GC1109 for anthrax has completed.
-
FDA approval · 2022-12-07FDA Approved: DOXYCYCLINE — Original Application (Par Health USA, LLC)
FDA approved a generic doxycycline product under an original new drug application by Par Health USA, LLC (ANDA216690).
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: VELOCITY: An Anthrax Vaccine Clinical Study [Phase 3]
Phase 3 clinical trial update for an anthrax vaccine (VELOCITY) has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study [Phase 2]
Phase 2 trial evaluating an anthrax vaccine (BioThrax) in combination with antibiotics has completed, with results posted in 2021.
-
FDA approval · 2021-06-02FDA Approved: RAXIBACUMAB — Supplemental Application (Emergent Manufacturing Operations Baltimore LLC)
FDA approved a supplemental application for manufacturing operations of RAXIBACUMAB (raxibacumab) by Emergent Manufacturing Operations Balti…
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: BARDA Securing Anthrax Immunity For the Elderly [Phase 2]
Phase 2 trial update on BARDA-supported anthrax immunity in the elderly has completed with results posted.
-
FDA approval · 2019-11-29FDA Approved: ANTHIM — Supplemental Application (Elusys Therapeutics, Inc.)
FDA approved a supplemental application for ANTHIM (obiltoxaximab) from Elusys Therapeutics, Inc.
-
CLINICAL_TRIALS trial_result · 2018-06-13Clinical Trial Update: Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) [Phase 1, Phase 2]
Phase 1/2 safety and pharmacokinetics study of Anthrax Immune Globulin Intravenous (AIGIV) has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-01-09Clinical Trial Update: Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed [Phase 4]
Phase 4 clinical trial assessing the effect of raxibacumab on the immunogenicity of Anthrax Vaccine Adsorbed has been completed with results…
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers [Phase 1]
Phase 1, single-dose, weight-based dose-escalation intravenous study of ETI-204 in healthy adult volunteers has completed; the trial evaluat…
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects [Phase 1]
This Phase 1 trial of anthrax vaccines Px563L and RPA563 in healthy adults has completed.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Anthrax Vaccine Clinical Trials [Phase 1]
Phase 1 clinical trials of an anthrax vaccine sponsored by NICHD have been completed, reporting early safety and immunogenicity data.
-
EMA withdrawal · 2017-06-02EMA Application withdrawn: Solithromycin Triskel EU Services (solithromycin) — Triskel EU Services Ltd
The EMA reports withdrawal of the Solithromycin application by Triskel EU Services Ltd for uses including tularemia, pneumonia, and anthrax.
-
CLINICAL_TRIALS trial_result · 2016-05-12Clinical Trial Update: PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine [Phase 1]
Phase 1 clinical trial of PA83-FhCMB plant-derived recombinant protective antigen (rPA) anthrax vaccine completed; the sponsor reports the s…
-
CLINICAL_TRIALS research · 2015-04-07Clinical Trial Update: VHA Clinicians and Bioterror Events: Interactive Web-based Learning [NA]
Completed clinical trial evaluating an interactive web-based learning module for VA clinicians on bioterror events related to smallpox and a…
-
CLINICAL_TRIALS trial_result · 2015-02-24Clinical Trial Update: A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels [Phase 2]
Phase 2 safety and immunogenicity study of an anthrax vaccine using three schedules and two dose levels has completed with results posted.